Clinical Progress

MK-4830: A Quick Look at Its R&D Progress and Clinical Results from the 2024 AACR

18 April 2024
5 min read

ILT4 is an immunosuppressive receptor commonly expressed on myeloid cells. Antagonism of ILT4 may induce a proinflammatory state and stimulate antitumor T-cell response, especially with PD-(L)1 blockade. On April 7, 2024,  the latest clinical data of the anti-ILT4 IgG4 monoclonal antibody, MK-4830, in combination with pembrolizumab (pembro) in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) were reported in 2024 AACR.

MK-4830's R&D Progress

The drug MK-4830 is a monoclonal antibody that targets LILRB2. Monoclonal antibodies are a type of drug that are designed to bind to specific proteins in the body and can be used for various therapeutic purposes. LILRB2 is the specific target of MK-4830, and it is involved in various diseases and conditions. In terms of therapeutic areas, MK-4830 is being developed for the treatment of neoplasms, endocrinology and metabolic diseases, urogenital diseases, and digestive system disorders. 

According to the Patsnap Synapse, MK-4830 has reached the highest phase of Phase 2 globally. And the clinical trial distributions for MK-4830 are primarily in the United States, China and United Kingdom. The key indication is Esophageal Squamous Cell Carcinoma. 

Detailed Clinical Result of MK-4830

This non-randomized, parallel assignment, open-labeled study (NCT03564691) was aimed to evacuate the safety, efficacy, and biomarker analyses for MK-4830 + pembro from the multi-cohort expansion phase of patients (pts) with previously untreated advanced HNSCC or NSCLC.  

In this study, pts aged ≥18 y with previously untreated advanced HNSCC and PD-L1 combined positive score (CPS) ≥1 (cohort D) or NSCLC regardless of PD-L1 status (cohorts E and F) were enrolled. Pts in all cohorts received either MK-4830 800 mg (cohorts D and E) or 1600 mg (cohort F) + pembro 200 mg Q3W for ≤35 cycles. Primary end points were safety and ORR per RECIST v1.1 by investigator assessment. Exploratory end points included DOR and PFS per RECIST v1.1 by investigator assessment and evaluating possible biomarkers of response to MK-4830 + pembro.

The result showed that at data cut-off (September 27, 2023), 35, 47, and 11 pts were enrolled and received treatment in cohorts D, E, and F, respectively. Median study follow-up was 34.4 mo (range, 26.5-42.4) in cohort D, 35.9 mo (22.4-39.8) in cohort E, and 38.7 mo (37.6-39.6) in cohort F. Adverse events (AEs) occurred in 33 pts (94%) in cohort D, 43 pts (91%) in cohort E, and 10 pts (91%) in cohort F. Treatment-related AEs (TRAEs) occurred in 20 pts (57%) in cohort D, 26 pts (55%) in cohort E, and 6 pts (55%) in cohort F; grade 3-5 TRAEs occurred in 5 pts (14%), 4 pts (9%), and 1 pt (9%), respectively. One pt in cohort E and 1 pt in cohort F died due to a TRAE (pneumonitis and pneumonia, respectively). ORR was 24% (95% CI, 11-41) in cohort D, 30% (17-45) in cohort E, and 27% (6-61) in cohort F. Median DOR was 16.4 mo (range, 2.2+ to 24.4+) in cohort D, 14.8 mo (4.2+ to 32.9+) in cohort E, and 8.4 mo (3.0-21.5) in cohort F. Median PFS was 5.2 mo (95% CI, 2.0-8.0) in cohort D, 4.3 mo (1.8-8.1) in cohort E, and 3.3 (1.2-7.6) in cohort F. In cohort D, T-cell-inflamed gene expression profile (TcellinfGEP) and tumor mutational burden (TMB) did not enrich for response to MK-4830 + pembro. In cohorts E and F, PD-L1 tumor proportion score (TPS) and TcellinfGEP trended higher in pts with response to MK-4830 + pembro than pts with no response; TMB did not trend with response.

It can be concluded that in pts with advanced HNSCC or NSCLC, first-line MK-4830 + pembro had a manageable AE profile with modest antitumor activity. Consistent with what was previously observed for pembro alone, a trend was observed between PD-L1 TPS and response to MK-4830 + pembro in pts with NSCLC.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

What is the Pharmaceutical Regulatory System of the European Union and its Member States?
"What" Series
2 min read
What is the Pharmaceutical Regulatory System of the European Union and its Member States?
18 April 2024
The EU's pharmaceutical regulatory system is a complex, multi-layered network with various agencies working together to safeguard the safety, efficacy, and quality of medicines in the European Economic Area.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 18
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 18
18 April 2024
April 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
NiKang Therapeutics Begins Phase 1/1b Trial with First Dose of Oral CDK2 Inhibitor NKT3447
Latest Hotspot
3 min read
NiKang Therapeutics Begins Phase 1/1b Trial with First Dose of Oral CDK2 Inhibitor NKT3447
18 April 2024
NiKang Therapeutics has administered the initial dose to a patient in its Phase 1/1b trial of NKT3447, an oral drug targeting CDK2 that decreases Cyclin E levels.
Read →
An analysis of IMM-27M's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
An analysis of IMM-27M's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
18 April 2024
On April 5, 2024, the latest clinical findings of IMM27M were unveiled at the 2024 AACR, demonstrating its potential effect and setting the stage for subsequent investigations.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.